• Myriad Genetics Q2 2026 revenue fell 11% to $190.7 million; net loss narrowed to $43.2 million, or $0.46 per share.
• Gross margin dropped 4.6 percentage points to 66.6%; operating loss narrowed to $38.9 million.
• Test volumes slipped 1% to 379,000; average revenue per test fell 9%, partly reflecting an $11 million revenue reduction tied to cash-collection estimates.
• Cancer Care Continuum volumes rose 6% to 95,000 while revenue fell 11% to $114.1 million; Prenatal Health volumes fell 9% to 144,000.
• Revised FY 2026 revenue outlook to $770-$790 million; suspended adjusted EBITDA guidance while launching the Ascend efficiency initiative.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000899923-26-000070), on July 30, 2026, and is solely responsible for the information contained therein.